Sanofi (SAN:CA) Q2 2026 Earnings Call July 30, 2026 7:00 AM EDT
Company Participants
Thomas Larsen – Head of Investor Relations & General Medicines
Belen Garijo Lopez – CEO & Director
François-Xavier Roger – Executive VP & CFO
Mike Quigley
Manuela Buxo – Executive VP & Head of Specialty Care
Roy Papatheodorou – Executive VP & General Counsel
Thomas Triomphe – Executive Vice President of Vaccines
Conference Call Participants
James Quigley – Goldman Sachs Group, Inc., Research Division
Sachin Jain – BofA Securities, Research Division
Peter Verdult – BNP Paribas, Research Division
Luisa Hector – Joh. Berenberg, Gossler & Co. KG, Research Division
Graham Glyn Parry – Citigroup Inc., Research Division
Simon Baker – Rothschild & Co Redburn, Research Division
David Risinger – Leerink Partners LLC, Research Division
Seamus Fernandez – Guggenheim Securities, LLC, Research Division
Michael Leuchten – Jefferies Financial Group Inc.
Richard Vosser – JPMorgan Chase & Co, Research Division
Matthew Weston – UBS Investment Bank, Research Division
Florent Cespedes – ODDO BHF Corporate & Markets, Research Division
James Gordon – Barclays Bank PLC, Research Division
Presentation
Thomas Larsen
Head of Investor Relations & General Medicines
Hello, everyone. This is Thomas Larsen from the Sanofi IR team. Welcome to the Second Quarter 2026 Conference Call for investors and analysts. Slides can be found on sanofi.com.
Please turn to Slide #3. Here are the forward-looking statements. We would like to remind you that information presented in this call contains forward-looking statements, which are subject to substantial risks and uncertainties that may cause actual results to differ materially. We encourage you to read the disclaimer in the presentation.
We also refer you to our Form 20-F on file with the U.S. SEC and our French universal registration document. We’re going to make comments on our performance using constant exchange rates and other non-IFRS measures. Numbers used are in millions of euros and for the second quarter, unless we stated otherwise.
